Completed NA INTERVENTIONAL NCT00413504

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)

Sponsor: Brigham and Women's Hospital

Conditions Deep Vein Thrombosis Pulmonary Embolism

Updated 5 times since 2017 Last updated: Feb 2, 2009 Started: Apr 30, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00413504, this NA trial focuses on Deep Vein Thrombosis and Pulmonary Embolism and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital
GlaxoSmithKline

Data source: Brigham and Women's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States